IL44023A - Fractionation of coagulation factor depleted blood serum and plasma - Google Patents
Fractionation of coagulation factor depleted blood serum and plasmaInfo
- Publication number
- IL44023A IL44023A IL44023A IL4402374A IL44023A IL 44023 A IL44023 A IL 44023A IL 44023 A IL44023 A IL 44023A IL 4402374 A IL4402374 A IL 4402374A IL 44023 A IL44023 A IL 44023A
- Authority
- IL
- Israel
- Prior art keywords
- block copolymer
- concentration
- plasma
- serum
- supernatant
- Prior art date
Links
- 210000002381 plasma Anatomy 0.000 title claims abstract description 27
- 210000002966 serum Anatomy 0.000 title claims abstract description 26
- 102000015081 Blood Coagulation Factors Human genes 0.000 title claims abstract description 16
- 108010039209 Blood Coagulation Factors Proteins 0.000 title claims abstract description 16
- 239000003114 blood coagulation factor Substances 0.000 title claims abstract description 16
- 238000005194 fractionation Methods 0.000 title claims description 12
- 229920001400 block copolymer Polymers 0.000 claims abstract description 48
- 239000002244 precipitate Substances 0.000 claims abstract description 42
- 239000006228 supernatant Substances 0.000 claims abstract description 41
- 108010088751 Albumins Proteins 0.000 claims abstract description 18
- 102000009027 Albumins Human genes 0.000 claims abstract description 18
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 12
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 12
- 210000000056 organ Anatomy 0.000 claims abstract description 10
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 7
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 27
- -1 polyoxypropylene Polymers 0.000 claims description 17
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 229920001451 polypropylene glycol Polymers 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 2
- 102100027378 Prothrombin Human genes 0.000 abstract description 11
- 108010094028 Prothrombin Proteins 0.000 abstract description 11
- 229940039716 prothrombin Drugs 0.000 abstract description 11
- 108010049003 Fibrinogen Proteins 0.000 abstract description 7
- 102000008946 Fibrinogen Human genes 0.000 abstract description 7
- 229940012952 fibrinogen Drugs 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 6
- 102000004506 Blood Proteins Human genes 0.000 abstract description 5
- 108010017384 Blood Proteins Proteins 0.000 abstract description 5
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract description 5
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract description 5
- 229940019700 blood coagulation factors Drugs 0.000 abstract description 2
- 238000010261 blood fractionation Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 239000000203 mixture Substances 0.000 description 15
- 230000000717 retained effect Effects 0.000 description 13
- 239000000725 suspension Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000008351 acetate buffer Substances 0.000 description 6
- 229920001983 poloxamer Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 6
- 102000005686 Serum Globulins Human genes 0.000 description 5
- 108010045362 Serum Globulins Proteins 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003463 adsorbent Substances 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 235000019731 tricalcium phosphate Nutrition 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108010068307 Alpha-Globulins Proteins 0.000 description 2
- 102000002572 Alpha-Globulins Human genes 0.000 description 2
- 102000006734 Beta-Globulins Human genes 0.000 description 2
- 108010087504 Beta-Globulins Proteins 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QMHLJNFGMZBHIP-UHFFFAOYSA-N oxirane;propane-1,2-diol Chemical compound C1CO1.CC(O)CO QMHLJNFGMZBHIP-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 108010058237 plasma protein fraction Proteins 0.000 description 2
- 229940081857 plasma protein fraction Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960005480 sodium caprylate Drugs 0.000 description 2
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 108010091934 Macroglobulins Proteins 0.000 description 1
- 102000018721 Macroglobulins Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003171 anti-complementary effect Effects 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000009582 blood typing Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32789373A | 1973-01-30 | 1973-01-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL44023A0 IL44023A0 (en) | 1974-05-16 |
| IL44023A true IL44023A (en) | 1977-05-31 |
Family
ID=23278536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL44023A IL44023A (en) | 1973-01-30 | 1974-01-20 | Fractionation of coagulation factor depleted blood serum and plasma |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS49102820A (enrdf_load_stackoverflow) |
| AU (1) | AU6495474A (enrdf_load_stackoverflow) |
| BE (1) | BE810217A (enrdf_load_stackoverflow) |
| CA (1) | CA984748A (enrdf_load_stackoverflow) |
| DE (1) | DE2403065A1 (enrdf_load_stackoverflow) |
| ES (1) | ES422767A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2215241B1 (enrdf_load_stackoverflow) |
| GB (1) | GB1449333A (enrdf_load_stackoverflow) |
| IL (1) | IL44023A (enrdf_load_stackoverflow) |
| ZA (1) | ZA74350B (enrdf_load_stackoverflow) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3944391A (en) * | 1974-12-27 | 1976-03-16 | Preventive Systems, Inc. | In vitro process for detecting endotoxin in a biological fluid |
| IL49752A (en) * | 1975-07-09 | 1979-07-25 | Kabi Ab | Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration |
| DK25877A (da) * | 1977-01-21 | 1978-08-15 | Nordisk Insulinlab | Fremgangsmaade til udvinding af renset albumin fra blodplasma |
| JPS5843369B2 (ja) * | 1977-09-10 | 1983-09-27 | 森六株式会社 | 血清蛋白質の分画方法 |
| US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
-
1974
- 1974-01-17 ZA ZA740350A patent/ZA74350B/xx unknown
- 1974-01-20 IL IL44023A patent/IL44023A/en unknown
- 1974-01-21 JP JP49009169A patent/JPS49102820A/ja active Pending
- 1974-01-23 DE DE2403065A patent/DE2403065A1/de not_active Withdrawn
- 1974-01-25 GB GB355774A patent/GB1449333A/en not_active Expired
- 1974-01-28 BE BE140217A patent/BE810217A/xx unknown
- 1974-01-29 AU AU64954/74A patent/AU6495474A/en not_active Expired
- 1974-01-29 CA CA191,229A patent/CA984748A/en not_active Expired
- 1974-01-29 FR FR7402807A patent/FR2215241B1/fr not_active Expired
- 1974-01-30 ES ES422767A patent/ES422767A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA984748A (en) | 1976-03-02 |
| BE810217A (fr) | 1974-05-16 |
| IL44023A0 (en) | 1974-05-16 |
| FR2215241B1 (enrdf_load_stackoverflow) | 1977-03-11 |
| JPS49102820A (enrdf_load_stackoverflow) | 1974-09-28 |
| GB1449333A (en) | 1976-09-15 |
| DE2403065A1 (de) | 1974-08-01 |
| ES422767A1 (es) | 1976-06-01 |
| ZA74350B (en) | 1974-11-27 |
| FR2215241A1 (enrdf_load_stackoverflow) | 1974-08-23 |
| AU6495474A (en) | 1975-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3956259A (en) | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate | |
| US4073886A (en) | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene | |
| US3770631A (en) | Clarification of blood serum and plasma | |
| Newman et al. | Methods for the production of clinically effective intermediate and high‐purity factor‐VIII concentrates | |
| CA2155630C (en) | Low temperature albumin fractionation using sodium caprylate as a partitioning agent | |
| US4188318A (en) | Simplified method for preparation of high yield, high purity Factor VIII concentrate | |
| US3682881A (en) | Fractionation of plasma using glycine and polyethylene glycol | |
| JP5178518B2 (ja) | 超高収率静注免疫グロブリン製剤 | |
| CA1213214A (en) | Preparation of highly purified human antihemophilic factor | |
| AU2006287833B2 (en) | An ultra-high yield intravenous immune globulin preparation | |
| US4876088A (en) | Gamma-globulin injectable solutions containing sorbitol | |
| EP0176926B1 (en) | Process for producing a high purity antihemophilic factor concentrate | |
| AU549584B2 (en) | Heat stabilization of plasma proteins | |
| US4087415A (en) | Antithrombin III | |
| US3839314A (en) | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene | |
| US4025500A (en) | Preparation of albumin by fractionation of blood plasma or serum | |
| US4164495A (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| US8293242B2 (en) | Ultra-high yield of alpha-1-anti-trypsin | |
| USRE31268E (en) | Method of recovering immunoglobulin using a polyol and an alkanoic acid | |
| IL44023A (en) | Fractionation of coagulation factor depleted blood serum and plasma | |
| EP0011739A1 (en) | Process for obtaining blood coagulation factor XIII derived from human placenta | |
| US3893990A (en) | Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene | |
| US3893991A (en) | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene | |
| Schwick | A Survey of the Production of Plasma Derivatives | |
| US4406886A (en) | Purification of antihemophilia factor VIII by precipitation with zinc ions |